Sökning: WFRF:(Espes Daniel) >
GABA induces a horm...
GABA induces a hormonal counter-regulatory response in subjects with long-standing type 1 diabetes
-
- Espes, Daniel, 1985- (författare)
- Uppsala universitet,Institutionen för medicinsk cellbiologi,Transplantation och regenerativ medicin,Science for Life Laboratory, SciLifeLab
-
- Liljebäck, Hanna (författare)
- Uppsala universitet,Institutionen för medicinsk cellbiologi,Institutionen för medicinska vetenskaper
-
- Hill, Henrik (författare)
- Uppsala universitet,Pediatrisk inflammations- och metabolismforskning samt barnhälsa
-
visa fler...
-
- Elksnis, Andris (författare)
- Uppsala universitet,Institutionen för medicinsk cellbiologi
-
- Caballero-Corbalán, José (författare)
- Uppsala universitet,Transplantation och regenerativ medicin
-
- Carlsson, Per-Ola (författare)
- Uppsala universitet,Institutionen för medicinsk cellbiologi,Transplantation och regenerativ medicin
-
visa färre...
-
(creator_code:org_t)
- 2021-10-11
- 2021
- Engelska.
-
Ingår i: BMJ Open Diabetes Research & Care. - : BMJ Publishing Group Ltd. - 2052-4897. ; 9
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://drc.bmj.com/...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: Experimentally, gamma-aminobutyric acid (GABA) has been found to exert immune-modulatory effects and induce beta-cell regeneration, which make it a highly interesting substance candidate for the treatment of type 1 diabetes (T1D). In many countries, including those in the European Union, GABA is considered a pharmaceutical drug. We have therefore conducted a safety and dose escalation trial with the first controlled-release formulation of GABA, Remygen (Diamyd Medical).Research design and methods: Six adult male subjects with long-standing T1D (age 24.8 +/- 1.5 years, disease duration 14.7 +/- 2.2 years) were enrolled in an 11-day dose escalation trial with a controlled-release formulation of GABA, Remygen. Pharmacokinetics, glucose control and hormonal counter-regulatory response during hypoglycemic clamps were evaluated at every dose increase (200 mg, 600 mg and 1200 mg).Results: During the trial there were no serious and only a few, transient, adverse events reported. Without treatment, the counter-regulatory hormone response to hypoglycemia was severely blunted. Intake of 600 mg GABA more than doubled the glucagon, epinephrine, growth hormone and cortisol responses to hypoglycemia.Conclusions: We find that the GABA treatment was well tolerated and established a counter-regulatory response to hypoglycemia in long-standing T1D. Further studies regarding not only the clinical potential of Remygen for beta-cell regeneration but also its potential use as hypoglycemic prophylaxis are warranted. Trail registration number and EudraCT2018-001115-73.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- diabetes mellitus
- type 1
- hypoglycemia
- receptors
- GABA-A
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas